Vaccine Info

Ad5-GUCY2C-PADRE Colon Cancer Vaccine

Description

Ad5-GUCY2C-PADRE is a replication-deficient human type 5 recombinant adenovirus (Ad5) vaccine encoding guanylyl cyclase C (GUCY2C) fused to the PAn DR Epitope (PADRE). GUCY2C, a paracrine hormone receptor producing the second messenger cyclic GMP (cGMP), is selectively expressed by intestinal epithelial cells and a subset of hypothalamic neurons, but not other tissues.  

Indication

Ad5-GUCY2C-PADRE is a cancer vaccine candidate indicated for the treatment of early-stage colorectal cancer.

Clinical Trial NCT01972737:  Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

The purpose of this study is to determine the safety, tolerability, and ability to stimulate hGCC-specific antibody and killer T cell immune responses of an Ad5-hGCC-PADRE vaccine in stage I and stage II Caucasian and African American colon cancer patients.

Updated
August 21st, 2019